BIOPHYTIS EUR0.8 (POST CONSOLIDATION)BIOPHYTIS EUR0.8 (POST CONSOLIDATION)BIOPHYTIS EUR0.8 (POST CONSOLIDATION)

BIOPHYTIS EUR0.8 (POST CONSOLIDATION)

No trades
See on Supercharts

0D1W fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 27, 2006 and is headquartered in Paris, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0D1W does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company